Last Updated : November 7, 2022
The class of sodium-glucose cotransporter 2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes. Recent published clinical evidence has provided further guidance on the role of SGLT2 inhibitors in type 2 diabetes, as well as other indications such as heart failure and chronic kidney disease. This Environmental Scan will assess the current reimbursement of the SGLT2 drug class relevant to public drug programs. The Environmental Scan will include the regulatory, exclusivity, CADTH Reimbursement Review, and reimbursement status of SGLT2 inhibitors for type 2 diabetes mellitus, heart failure, and chronic kidney disease.
Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.
The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.